反応式
CNC(=O)OC(C)(C)C.O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccc(OS(=O)(=O)C(F)(F)F)cc34)cccc12>C1COCCO1.CC1(C)c2cccc(P(c3ccccc3)c3ccccc3)c2Oc2c(P(c3ccccc3)c3ccccc3)cccc21.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C([O-])[O-].[Cs+].[Cs+].[Pd].[Pd]>CN(C(=O)OC(C)(C)C)c1ccc2sc3c(-c4cccc5c(=O)cc(N6CCOCC6)oc45)cccc3c2c1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 110 °C
実験手順
A solution of tert-butyl methylcarbamate (35.0 mg, 0.27 mmol) in dioxane (1.781 ml) was added to a stirred mixture of 6-(2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-2-yl trifluoromethanesulfonate (100 mg, 0.18 mmol), TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (4.08 mg, 4.45 µmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (5.15 mg, 8.90 µmol) and cesium carbonate (232 mg, 0.71 mmol). The resulting mixture was stirred under nitrogen at 110 °C for 3 hours. The cooled reaction mixture was diluted with methanol and the residue was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH and evaporated to dryness to afford tert-butyl methyl(6-(2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-2-yl)carbamate (97 mg, 100 %) as a orange residue. 100% assumed and this was progressed to the next stage with no further purification.
出典と根拠
- ORDレコード
- ord-33a377364ac14bd183dfd7eb0108a408
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…